Advertisement
UK markets closed
  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     
  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     
  • AIM

    779.67
    +6.64 (+0.86%)
     
  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     
  • Bitcoin GBP

    52,932.34
    +663.86 (+1.27%)
     
  • CMC Crypto 200

    1,379.30
    +48.69 (+3.66%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • DOW

    40,589.34
    +654.27 (+1.64%)
     
  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     
  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     
  • DAX

    18,417.55
    +118.83 (+0.65%)
     
  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?

It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth market. Let's survey the competitive landscape as it is today, and think through how it's likely to develop.